Ensitrelvir (also known as S-217622; trade name Xocova) is
an orally bioavailable, non-covalent, non-peptidic, SARS-CoV-2 3CL
protease inhibitor (IC50=13 nM) effective against the Omicron variant.
It is an antiviral drug developed by Shionogi in partnership with
Hokkaido University. It became the first Japanese domestic pill to treat
COVID-19, third to be regulatorally approved in Japan; in February 2022
纯度:≥98%
CAS:2647530-73-0